Celyad Oncology SA
CLYYF
$0.20
-$0.21-51.22%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.30% | -17.03% | 41.53% | 40.36% | 19.52% |
| Total Depreciation and Amortization | -6.01% | -13.68% | -58.69% | -57.84% | -42.99% |
| Total Amortization of Deferred Charges | -- | -- | 18.59% | 20.98% | -- |
| Total Other Non-Cash Items | 361.90% | 324.53% | -149.04% | -150.03% | 102.78% |
| Change in Net Operating Assets | 150.00% | 145.82% | 95.83% | 95.75% | 98.49% |
| Cash from Operations | -21.94% | -12.11% | 58.94% | 58.12% | 66.40% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -42.86% | -41.84% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 100.00% | 100.00% | -243.24% |
| Cash from Investing | -- | -- | 102.66% | 102.70% | -112.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 12.05% | 12.05% | -58.49% | -58.49% | 9.78% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -102.79% | -102.79% | 4,360.00% | 4,360.00% | 22,680.00% |
| Cash from Financing | -106.60% | -106.06% | -91.54% | -91.37% | 2,209.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -20.00% | 0.00% | -- | -- | -- |
| Net Change in Cash | -363.94% | -326.48% | -199.06% | -201.05% | 89.74% |